Collegium Pharmaceutical(COLL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [26][32] - The company generated robust operating cash flows of $329.3 million and ended the year with $386.7 million in cash equivalents and marketable securities, an increase of approximately $224 million from the end of 2024 [7][32] - GAAP net income for the fourth quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM net revenue reached $148.9 million in 2025, up 48% compared to pro forma 2024 revenue, with prescriptions growing by 20% year-over-year [6][27] - The pain portfolio generated $631.7 million in 2025, reflecting a 6% year-over-year growth, with all three core pain medicines showing full-year growth [7][22] - Belbuca net revenue was $221.7 million in 2025, up 5% year-over-year, while Xtampza ER net revenue was $199.3 million, up 4% year-over-year [27] Market Data and Key Metrics Changes - Jornay's market share in the long-acting branded methylphenidate market grew to nearly 26% in the fourth quarter, up 6.5 percentage points year-over-year [19] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [19][20] - The prescriber base for Jornay reached an all-time high of over 29,000, up 21% year-over-year [19] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and disciplined capital deployment to enhance shareholder value [4][11] - The company aims to expand its portfolio through business development, targeting assets that are commercial or near-commercial with a focus on neuropsychiatry, pediatrics, and pain [36] - The company has made significant investments in sales and marketing to support Jornay's growth, including expanding the sales force and launching new marketing campaigns [12][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive growth in 2026, expecting Jornay revenue to be in the range of $190 million-$200 million, representing over 30% annual growth [12][33] - The company anticipates a modest quarter-over-quarter decline in revenues in Q1 2026 due to typical seasonal dynamics, but remains optimistic about long-term growth prospects [34] - Management highlighted the importance of maintaining broad payer access for Jornay and securing formulary access under a major commercial healthcare plan [22] Other Important Information - The company published its 2025 ESG report, emphasizing its commitment to social responsibility alongside financial success [5] - The company closed a $980 million syndicated credit facility, improving its interest rate and debt terms, which provides additional flexibility for future business development opportunities [9][35] Q&A Session Summary Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management noted that there have not been any material changes in competitive dynamics or future launches that could impact Jornay demand, emphasizing its differentiation in the market [41] Question: Can you help us frame how you're thinking about the ramp to peak sales for Jornay? - Management stated that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing activities throughout 2026 [44] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are highly promotionally sensitive, and the sales team is focused on navigating the complex payer environment [47]